Skip to main content

Table 2 Univariate analysis of factors predicting recurrence-free and overall survival

From: Overexpression of a panel of cancer stem cell markers enhances the predictive capability of the progression and recurrence in the early stage cholangiocarcinoma

Variable

Median RFS (months)

Recurrence-free survival

Median

OS (months)

Overall survival

HR

P (95% CI)

HR

P (95% CI)

Overall

15.0

  

17.0

  

Sex

 Female

13.0

1

0.336 (0.853–1.593)

16.9

1

0.270 (0.872–1.634)

 Male

15.0

1.166

17.4

1.193

Age (year)

 Less than 61

16.0

1

0.208 (0.899–1.630)

19.2

1

0.032 (1.028–1.876)

 61 or greater

13.0

1.211

16.3

1.388

Tumor site

 Intrahepatic

12.5

1

0.449 (0.664–1.199)

16.0

1

0.560 (0.680–1.232)

 Extrahepatic

16.0

0.892

18.5

0.915

Histology type

 Papillary

16.0

1

0.253 (0.884–1.599)

17.6

1

0.759 (0.779–1.409)

 Others

13.0

1.189

16.3

1.047

Primary tumor (T)

 I, II

18.0

1

< 0.001 (1.956–3.771)

22.0

1

< 0.001 (1.907–3.629)

 III, IV

9.0

2.716

11.0

2.630

Reginal lymph nodes (N) metastasis

 No

17.0

1

0.001 (1.265–2.362)

20.0

1

< 0.001 (1.442–2.704)

 Yes

10.5

1.729

13.0

1.975

Distant metastasis (M)

 No

15.0

1

0.762 (0.432–3.150)

17.0

1

0.519 (0.513–3.751)

 Yes

12.0

1.166

13.5

1.387

TNM stage

 I, II

18.0

1

< 0.001 (1.576–2.986)

21.6

1

< 0.001 (1.711–3.255)

 III, IV

10.0

2.169

12.8

2.360

Post-operative CMT

 No

15.0

1

0.933 (0.727–1.340)

16.9

1

0.556 (0.671–1.239)

 Yes

15.0

0.987

19.0

0.912

CD44

 Low

18.0

1

 0.007 (1.129–2.170)

22.0

1

 0.001 (1.250–2.399)

 High

13.0

1.565

16.1

1.732

 

CD44v6

 Neg.

17.0

1

0.001 (1.234–2.311)

19.2

1

0.006 (1.128–2.081)

 Pos.

11.0

1.689

12.8

1.532

CD44v8-10

 Neg.

16.0 

1

0.007 (1.125–2.072)

20.0

1

< 0.001 (1.271–2.352)

 Pos.

13.0

1.527

14.1

1.729

CD133

 Neg.

16.0

1

0.103 (0.949–1.765)

18.1

1

0.083 (0.965–1.794)

 Pos.

12.5

1.295

16.1

1.316

EpCAM

  Low

14.0

1

0.135 (0.594–1.073)

16.3

1

0.261 (0.629–1.134)

 High

16.0

0.798

18.6

0.844

ALDH1A1

 Low

11.0

1

0.075 (0.569–1.028)

16.0

1

0.022 (0.525–0.950)

 High

17.0

0.765

19.9

0.706

  1. TNM primary tumor-node-metastasis, post-operative, CMT post-operative chemotherapeutic treatment, HR hazard ratio, 95% CI 95% confidence interval, CD44 cluster of differentiation 44, CD44v CD44 variant, CD133 cluster of differentiation 133, EpCAM epithelial cell adhesion molecules, ALDH1A1 aldehyde dehydrogenase 1A1, TNM primary tumor-node-metastasis, Neg negative expression, Pos positive expression
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us